Navigation Links
Thomson Reuters Cortellis Drives Drug Discovery and Development With Powerful New Web Services

PHILADELPHIA, and LONDON, Feb. 28, 2012 /PRNewswire/ -- Thomson Reuters announced the availability of Cortellis for Informatics, a new capability that speeds access to critical life sciences research and development information found on its premiere life sciences platform, Thomson Reuters Cortellis.

Cortellis for Informatics uses sophisticated application programming interfaces (APIs) to enhance the research and development process by delivering real-time access to powerful information and tools for biopharmaceutical competitive intelligence, drug pipeline, and drug research and development.

Each API integrates Thomson Reuters data with proprietary content and public information sources into a comprehensive view that is customized to meet the needs of a company, team or individual researcher. With Cortellis for Informatics, data can be shared in a number of ways, including dashboards, custom reports and alerts, and intranet and mobile applications.

"We worked closely with Thomson Reuters during their development and testing phases, and I am delighted to say that the Cortellis APIs exceed my expectations and allow us to take advantage of Thomson Reuters content in the systems that drive our business," said Dr. William Hayes, director of Decision Support at Biogen Idec.

"For life sciences professionals, Cortellis for Informatics is a significant step forward," said Wendy Hamilton, senior vice president at Thomson Reuters. "The advanced options for obtaining information give customers access to our content beyond Cortellis' highly intuitive web portal. Information can now be incorporated directly on the user's preferred systems, customized to their needs, creating additional opportunities for integration across the entire organization."

Cortellis for Informatics streamlines information sharing across all levels of the organization. Instead of using multiple systems to manage workflows, researchers access up-to-the-minute news in the office, in meetings or at the bench. This ability to deploy high-quality Thomson Reuters information across the whole company in real time within internal systems provides greater opportunities for collaboration in the scientific search and discovery process.

Cortellis for Informatics provides web services for investigational drugs, drug targets, ontologies, patents, clinical trials and analytics.

For more information on Cortellis, visit

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals.  We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 55,000 people and operates in over 100 countries. For more information, go to

SOURCE Thomson Reuters
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
2. Despite Decline in Share of Global Output, U.S. Science Impact Still Strong, Says Thomson Reuters
3. Thomson Reuters Names Hottest Researchers and Papers of 2007-2008
4. APS Healthcare and Thomson Reuters to Manage New York States Medicaid Clinical Best Practices Review Program
5. Thomson Reuters Commemorates World IP Week with Series of Strategic Intellectual Property Seminars Across the U.S.
6. Thomson Reuters Examines Highly Cited Research in Bioterrorism
7. Thomson Reuters Makes Disease Briefing on Influenza Covering H1N1 (Swine Flu) Publicly Available
8. Brazils Scientific Research On The Rise, Thomson Reuters Study Finds
9. Thomson Reuters Partners With Sagient Research
10. Thomson Reuters Announces 2009 Edition of the CMR International Pharmaceutical R&D Factbook
11. Thomson Reuters Joins the InChI Trust
Post Your Comments:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
Breaking Biology Technology:
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):